Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.
Patient characteristics by treatment group
| Doxorubicin + cyclophos- phamide (n = 15) |
Doxorubicin + placebo (n = 17) |
P value | |
|---|---|---|---|
| Age (years) | 0.83 | ||
| Mean | 8.25 ± 2.57 | 8.47 ± 3.07 | |
| Median | 8 | 9 | |
| Range | 5–13 | 2–14 | |
| Body weight (mean in kg) |
31.7 ± 4.1 | 33.3 ± 3.2 | 0.76 |
| Sex | 1.0 | ||
| Male | 10 (66.7%) | 12 (64.7%) | |
| Female | 5 (33.3%) | 5 (35.2%) | |
| Substage | 0.32 | ||
| a | 12 (80.0%) | 16 (94.1%) | |
| b | 3 (20.0%) | 1 (5.9%) | |
| Immuno- phenotype |
0.49 | ||
| B | 6 (40.0%) | 5 (29.4%) | |
| T | 2 (13.3%) | ||
| Null | 2 (11.8%) | ||
| Hypercalcaemia | 2 (13.3%) | 1 (5.9%) | 0.58 |
